HC Wainwright Analysts Cut Earnings Estimates for IN8bio

IN8bio, Inc. (NASDAQ:INAB) – Stock analysts at HC Wainwright decreased their Q2 2025 earnings per share (EPS) estimates for shares of IN8bio in a note issued to investors on Thursday, May 8th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($0.05) per share for the quarter, down from their previous forecast of ($0.04). HC Wainwright currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for IN8bio’s current full-year earnings is ($0.56) per share. HC Wainwright also issued estimates for IN8bio’s FY2025 earnings at ($0.19) EPS and FY2026 earnings at ($0.19) EPS.

IN8bio Price Performance

INAB opened at $0.16 on Monday. The stock’s 50-day moving average price is $0.18 and its 200 day moving average price is $0.25. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of 0.05. IN8bio has a 12-month low of $0.13 and a 12-month high of $1.74. The firm has a market cap of $14.52 million, a price-to-earnings ratio of -0.21 and a beta of 0.23.

IN8bio (NASDAQ:INAB) last posted its earnings results on Thursday, May 8th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.01).

Institutional Investors Weigh In On IN8bio

Large investors have recently bought and sold shares of the stock. BIOS Capital Management LP purchased a new position in IN8bio during the 4th quarter worth approximately $2,212,000. Alyeska Investment Group L.P. lifted its holdings in shares of IN8bio by 1,064.5% in the 4th quarter. Alyeska Investment Group L.P. now owns 5,063,291 shares of the company’s stock valued at $1,302,000 after buying an additional 4,628,482 shares during the period. Jane Street Group LLC lifted its holdings in shares of IN8bio by 296.7% in the 4th quarter. Jane Street Group LLC now owns 115,919 shares of the company’s stock valued at $30,000 after buying an additional 86,696 shares during the period. Geode Capital Management LLC lifted its holdings in shares of IN8bio by 56.5% in the 4th quarter. Geode Capital Management LLC now owns 515,193 shares of the company’s stock valued at $133,000 after buying an additional 185,919 shares during the period. Finally, Franklin Resources Inc. acquired a new stake in shares of IN8bio in the 4th quarter valued at approximately $1,465,000. Hedge funds and other institutional investors own 92.05% of the company’s stock.

IN8bio Company Profile

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.